Recursion Pharmaceuticals (RXRX)
About
Business overview of Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Key Insights
Critical company metrics and information
Share Price
$7.26Market Cap
$2.84 BillionTotal Outstanding Shares
383.72 Million SharesTotal Employees
500Dividend
No dividendIPO Date
April 16, 2021SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQType
Common StockPhone Number
(385) 269-0203Address
41s rio grande street, Salt lake city, UT, 84101Homepage
https://www.recursion.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $374.14 Million |
| Net Cash Flow From Operating Activities | $-317.82 Million |
| Net Cash Flow From Investing Activities, Continuing | $-17.89 Million |
| Net Cash Flow From Investing Activities | $-17.89 Million |
| Net Cash Flow | $38.62 Million |
| Net Cash Flow From Financing Activities | $374.14 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $-1.54 |
| Cost Of Revenue | $42.33 Million |
| Gross Profit | $22.86 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Net Income/Loss Available To Common Stockholders, Basic | $-377.75 Million |
| Income/Loss From Continuing Operations Before Tax | $-382.95 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $93.05 Million |
| Assets | $726.50 Million |
| Noncurrent Assets | $252.33 Million |
| Accounts Payable | $2.26 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Other Non-current Assets | $133.82 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2025 Financhle. All Rights Reserved.